Keisha Gibson, MD, MPH, discusses what an FDA approval of obinutuzumab (Gazyva) would mean for patients with the rare disease INS.
Keisha Gibson, MD, MPH
Advertisement
Keisha Gibson, MD, MPH, is a pediatric nephrologist and Division Chief of the Pediatric Nephrology Division at the UNC School of Medicine.
Articles by Keisha Gibson, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Olezarsen (Tryngolza) for Severe Hypertriglyceridemia
2
Q&A: CKM Care, IRA Policy, and Specialty Silos, With Rishi Wadhera, MD, MPP, MPhil
3
Highlighting FDA-Approved Therapies in Atopic Dermatitis, With Chris Bunick, MD, PhD
4
ILD as a Cardiopulmonary Disease: Cardiology's Role in Management
5